Publications dans lesquelles il/elle collabore avec Carlos Luri Rey (12)

2024

  1. Regional and intratumoral adoptive T-cell therapy

    Immuno-Oncology and Technology, Vol. 24

2023

  1. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  2. Facts and Hopes on Neutralization of Protumor Inflammatory Mediators in Cancer Immunotherapy

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 23, pp. 4711-4727

  3. Interleukin-18 in cancer immunology and immunotherapy

    Expert Opinion on Therapeutic Targets, Vol. 27, Núm. 11, pp. 1035-1042

  4. Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity

    Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198

  5. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 668-682

  6. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    OncoImmunology, Vol. 12, Núm. 1

  7. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

    Cell Reports Medicine, Vol. 4, Núm. 4

  8. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

    Cell Reports Medicine, Vol. 4, Núm. 3

2022

  1. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

    Cancer research, Vol. 82, Núm. 23, pp. 4373-4385

  2. Novel strategies exploiting interleukin-12 in cancer immunotherapy

    Pharmacology and Therapeutics, Vol. 239

  3. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3